Key Points
- CEO purchase: Century Therapeutics CEO Brent Pfeiffenberger bought 35,000 shares on Nov. 19 at $0.50 each ($17,500), bringing his total holdings to 3,271,453 shares (a 1.08% increase).
- Mixed insider activity: The purchase follows sales by Pfeiffenberger (notably 32,456 shares on Nov. 17 at $0.45), indicating recent buying after earlier divestitures.
- Stock and outlook: IPSC traded at $0.48 (down 2.8%) with a $41.65M market cap; the company reported EPS of -$0.32 beating estimates but remains unprofitable, and analysts' average rating is "Hold" with a $3.40 target.
Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) CEO Brent Pfeiffenberger acquired 35,000 shares of the stock in a transaction on Wednesday, November 19th. The shares were acquired at an average price of $0.50 per share, with a total value of $17,500.00. Following the purchase, the chief executive officer owned 3,271,453 shares in the company, valued at $1,635,726.50. This represents a 1.08% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Brent Pfeiffenberger also recently made the following trade(s):
- On Monday, November 17th, Brent Pfeiffenberger sold 32,456 shares of Century Therapeutics stock. The shares were sold at an average price of $0.45, for a total value of $14,605.20.
- On Monday, November 17th, Brent Pfeiffenberger sold 32,456 shares of Century Therapeutics stock. The stock was sold at an average price of $0.45, for a total transaction of $14,605.20.
- On Monday, September 8th, Brent Pfeiffenberger sold 488 shares of Century Therapeutics stock. The shares were sold at an average price of $0.50, for a total transaction of $244.00.
Century Therapeutics Trading Down 2.8%
NASDAQ IPSC traded down $0.01 during trading hours on Friday, reaching $0.48. 116,842 shares of the company traded hands, compared to its average volume of 783,431. The stock has a market capitalization of $41.65 million, a PE ratio of -1.48 and a beta of 1.80. Century Therapeutics, Inc. has a 12 month low of $0.34 and a 12 month high of $1.83. The company has a 50 day moving average of $0.54 and a two-hundred day moving average of $0.55.
Century Therapeutics (NASDAQ:IPSC - Get Free Report) last issued its earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.39) by $0.07. Century Therapeutics had a negative net margin of 19.10% and a negative return on equity of 10.01%. On average, equities research analysts anticipate that Century Therapeutics, Inc. will post -1.61 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several equities analysts recently issued reports on the company. Leerink Partners restated a "market perform" rating and set a $2.00 price objective (down from $7.00) on shares of Century Therapeutics in a research note on Monday. Leerink Partnrs lowered shares of Century Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Monday. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Century Therapeutics in a research report on Wednesday, October 8th. Finally, Wall Street Zen lowered shares of Century Therapeutics from a "hold" rating to a "sell" rating in a research note on Monday, October 20th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $3.40.
Get Our Latest Stock Analysis on IPSC
Hedge Funds Weigh In On Century Therapeutics
Hedge funds have recently made changes to their positions in the business. Bank of America Corp DE increased its stake in Century Therapeutics by 109.1% in the 4th quarter. Bank of America Corp DE now owns 66,043 shares of the company's stock worth $67,000 after purchasing an additional 34,466 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Century Therapeutics by 26.9% during the first quarter. Goldman Sachs Group Inc. now owns 179,635 shares of the company's stock worth $86,000 after buying an additional 38,052 shares in the last quarter. Prudential Financial Inc. acquired a new stake in Century Therapeutics during the second quarter valued at approximately $25,000. Qube Research & Technologies Ltd bought a new stake in shares of Century Therapeutics in the 2nd quarter worth about $38,000. Finally, AQR Capital Management LLC lifted its position in Century Therapeutics by 358.9% during the 1st quarter. AQR Capital Management LLC now owns 111,079 shares of the company's stock worth $53,000 after buying an additional 86,875 shares in the last quarter. Institutional investors and hedge funds own 50.20% of the company's stock.
Century Therapeutics Company Profile
(
Get Free Report)
Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
